NCT00705419View on ClinicalTrials.gov

Registry to Assess Long-term Outcome in HIV Subjects Who Participated in Phase 2 and 3 Clinical Trials Involving Vicriviroc (Study P04999)

CompletedOBSERVATIONAL
Enrollment

180

Participants

Timeline

Start Date

July 31, 2007

Primary Completion Date

September 30, 2010

Study Completion Date

September 30, 2010

Conditions
HIV Infections
Interventions
DRUG

Vicriviroc maleate

Follow-up for subjects who previously received 30 mg tablet administered once daily according to the parent protocol.

DRUG

Vicriviroc maleate

Follow-up for subjects who previously received 20 mg tablet administered once daily according to the parent protocol.

DRUG

Placebo

Follow-up for subjects who previously received placebo tablet administered once daily according to the parent protocol.

DRUG

Emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg

Follow-up for subjects who previously received active control consisting of emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg combination tablet administered once daily according to the parent protocol.

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00705419 - Registry to Assess Long-term Outcome in HIV Subjects Who Participated in Phase 2 and 3 Clinical Trials Involving Vicriviroc (Study P04999) | Biotech Hunter | Biotech Hunter